Monika Rappe is Head of Tech at SPP, where she drives the company’s evolution to a fast‑moving, tech‑driven organisation. With roots in product management at Siemens and nearly a decade as management consultant at McKinsey, Monika brings a mix of strategy and execution. Since joining SPP, she has held roles spanning Product, Operations and Innovation leadership. Today she focuses on scaling modern engineering, responsible AI, and rapid experimentation to unlock new growth.
Donald MacArthur is an oil and gas professional with over 25 years’ experience in the UKCS, specialising in late-life asset management and well decommissioning. As Operations Director and Wells Technical Authority at THREE60 Energy, he leads the safe and efficient management of wells and pipelines, with a strong focus on integrity and end-of-life delivery. Donald has progressed through a range of technical and leadership roles within the company since 2004, including Drilling Superintendent and Well Engineering Manager, building extensive experience in well operations, integrity management and abandonment across the full asset lifecycle.
“Genady Chybranov heads a dedicated BFSI Centre of Excellence, leading a specialist team with deep financial‑services expertise. He brings 20+ years of hands‑on experience designing and operating data and AI systems in regulated environments, with a sharp focus on agentic AI, model risk and controls, and enterprise architectures that are compliant by design (AI Act, DORA, NIS2).
Genady has held senior technology roles at Barclays and served as CTO for Financial Services at Hitachi, where he built and scaled production systems across banking and insurance. He is an active member of the Open Finance and Smart Payments working groups at the European Banking Association, where his current work explores Agentic Finance—from customer‑owned agents to machine‑to‑machine transactions and the governance patterns that make them safe.
Based in Stockholm, Joep Muselaers leads the Solutions Engineering teams for Cloudera across the Nordics and Benelux, focusing on the deployment of scalable data and AI strategies. With a tenured background at IBM and Sun Microsystems, he specializes in moving financial institutions from legacy infrastructure to hybrid-cloud architectures that support enterprise-grade machine learning. His current work centers on the industrialization of AI for high-stakes finance, specifically operationalizing fraud detection, anti-money laundering (AML), and regulatory compliance.
Stanko has over 20 years of experience in the resources industry. Working in roles spanning technology commercialisation, operations commissioning and financial implementation/investment. He leads a dynamic team focused on advancing projects and operations and driving innovation across the milling, flotation, leaching, smelting, refining and recycling value chain.
Van Zyl Engelbrecht (M.Sc (Med)) serves as the Head of Country Operations for the United Kingdom within AstraZeneca’s Rare Disease Research Unit (Alexion Pharmaceuticals). He is deeply committed to advancing innovative therapeutic approaches and ensuring that patients gain timely access to transformative treatments.
In his role, Van Zyl works at the intersection of scientific, regulatory, and operational disciplines, maintaining direct engagement with the complexities of clinical development. He takes great pride in the meaningful contributions he and his team make toward the successful delivery of compliant, high‑quality, and often highly complex clinical trials. His leadership is grounded in scientific rigor, operational excellence, and an unwavering focus on improving patient outcomes.
Biotech executive with 20+ years of experience driving innovation at the intersection of science, medicine, and technology. Currently VP, Head of Translational Medicine at Verge Genomics, where I built the function from the ground up and advanced neurology programs through Phase 2/3 readiness using FDA-validated biomarkers. Previously at Pfizer, I led cross-functional teams delivering novel digital endpoints, secured FDA/EMA alignment, and helped advance Ponsegromab from Phase 1 to Phase 2/3. At Biogen, I drove digital diagnostics initiatives, advanced technologies in Alzheimer’s and stroke, and helped spin out a new venture. I also founded a digital diagnostics startup, Usin’Life, which exited with a few assets. Passionate about advancing therapies for patients with high unmet medical needs, I bring expertise in translational medicine, biomarker strategy (digital & fluid), regulatory engagement, using technology ( including AI/ML !) and partnerships across biotech, pharma, and academia.
A highly accomplished physician, oncologist, pathologist, scientist, and senior medical leader with over 30 years of expertise in medicine and biopharmaceutical research and development, particularly in oncology. Renowned for proficiency in immuno-oncology, vaccine development, and fostering strategic collaborations across government, academia, hospitals, and industry. Demonstrates comprehensive expertise in clinical development, medical affairs, and navigating regulatory submissions (IND, BLA/NDA), with a proven record in leading and mentoring multidisciplinary teams. Skilled in building and guiding global oncology portfolios for diverse organizations, showcasing outstanding business acumen as a co-founder, board member, and a pivotal contributor to business development and alliance management. An extensive academic career includes mentoring, leading major clinical and research initiatives, and securing substantial research funding. Held key leadership roles such as Division Director, Department Head, and US Head of Global Oncology Development Unit. Committed to nurturing talent, team integration, and delivering impactful results, with exceptional communication skills that make complex scientific concepts accessible to diverse audiences. In addition to extensive scientific and medical accomplishments, am also a passionate advocate for human rights and social equity, recognizing socioeconomic inequalities as a profound threat to human well-being and a key driver of disease, necessitating decisive political action. Ran twice for President of the Democratic Republic of Congo, championing a platform focused on political and socioeconomic reforms, and advancing pro-poor policies.
Digital health product lead with expertise in SaMD, AI/ML-enabled screening, and clinical decision-support tools, with a track record of delivering multiple diagnostic devices that have achieved global regulatory clearance and market launch. My work spans diagnostics and digital health products across neurology, gastroenterology, oncology, and rare diseases.My role centers on building digital diagnostics platform capability—a reusable diagnostic foundation that supports therapeutic programs across the enterprise. This includes defining diagnostic value propositions, evidence requirements, technology development pathways, algorithm deployment frameworks, clinical workflow integration, and digital productization models that scale across the US, EU, Japan, and China.Backed by a strong foundation in regulated diagnostic development, I bring execution-focused leadership across the full product lifecycle—from requirements definition and validation planning to cross-functional alignment with clinical, translational science, regulatory, commercial, and global development partners.Previously a co-founder of a connected-health startup, I combine an innovation mindset with enterprise-level product leadership to shape Takeda’s approach to digital diagnostics, diagnostic algorithms, and clinical decision-support solutions.